Skip to main content
. 2022 Jun 4;27(11):3617. doi: 10.3390/molecules27113617

Figure 9.

Figure 9

Evaluation of CM-398 in an operant model of antinociception using constrictive nerve injury (CCI)-conditioned place preference (CPP). (A) Schematic representation of the CCI/CPP operant model of pain protocol; (B) Dose-dependent antinociception of CM-398 following i.p. administration in the mouse CCI/CPP operant pain model. Negative control mice were treated with vehicle (5% DMSO, i.p.; second pair of bars from left) and positive control mice were treated with the kappa opioid agonist U50,488 (leftmost pair of bars). All points represent differences in time spent on the drug-paired side ± SEM tested in 15–20 mice/drug. * = postconditioning response (striped bars) significantly different from matching pre-CPP response (matching open bars), p < 0.05; two-way ANOVA with Sidak’s post hoc test.